News GLP-1 drugs linked to pancreatitis, gallbladder problems Users of weight-loss therapies based on GLP-1 agonists have been warned to be aware of a rare complication, pancreatitis, that can be severe.
News Roche claims midstage win for obesity injectable Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?
News Wegovy pill shows strong early uptake, as rival looms Encouraging early sales data for oral Wegovy has buoyed Novo Nordisk, as Lilly waits for an FDA decision on its rival orforglipron, now due in Q2.
News JPM: Novo Nordisk CEO gives insight into new strategy Novo Nordisk CEO Mike Doustdar covers oral Wegovy, DTC sales channels, and an under-appreciated obesity pipeline in a wide-ranging presentation.
News FDA seeks changes to GLP-1, flu shot labels The FDA has asked manufacturers of GLP-1 drugs used for weight loss to remove warnings of suicidal thinking, but added warnings to flu shots.
News Study finds weight returns more quickly in GLP-1 users People who use drugs like GLP-1 agonists to lose weight regain it more quickly than those who use a conventional approach of diet and exercise.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.